Definitions
from Wiktionary, Creative Commons Attribution/Share-Alike License.
- noun A
monoclonal antibody which is linked withyttrium-90 as the drugibritumomab tiuxetan
Etymologies
Sorry, no etymologies found.
Support
Help support Wordnik (and make this page ad-free) by adopting the word ibritumomab.
Examples
-
The new drugs include rituximab (sold as Rituxan), with four boxed warnings, and ibritumomab tiuxetan (Zevalin), with two boxed warnings, among others.
-
The new drugs include rituximab (sold as Rituxan), with four boxed warnings, and ibritumomab tiuxetan (Zevalin), with two boxed warnings, among others.
-
ZEVALIN (ibritumomab tiuxetan) is indicated for the treatment of patients with previously untreated follicular non-Hodgkin's Lymphoma (NHL), who achieve a partial or complete response to first-line chemotherapy.
-
ZEVALIN (ibritumomab tiuxetan) is indicated for the treatment of patients with previously untreated follicular non-Hodgkin's Lymphoma (NHL), who achieve a partial or complete response to first-line chemotherapy.
-
The new drugs include rituximab (sold as Rituxan), with four boxed warnings, and ibritumomab tiuxetan (Zevalin), with two boxed warnings, among others.
-
The new drugs include rituximab (sold as Rituxan), with four boxed warnings, and ibritumomab tiuxetan (Zevalin), with two boxed warnings, among others.
-
The new drugs include rituximab (sold as Rituxan), with four boxed warnings, and ibritumomab tiuxetan (Zevalin), with two boxed warnings, among others.
-
ZEVALIN (ibritumomab tiuxetan) is indicated for the treatment of patients with previously untreated follicular non-Hodgkin's Lymphoma (NHL), who achieve a partial or complete response to first-line chemotherapy.
unknown title 2009
-
Data from clinical trials suggest that radio-immunotherapy (RIT) consolidation therapy is an important treatment approach for patients with follicular lympho ma (FL), with striking phase 3 results recently published for 90Y-ibritumomab tiuxetan
-
-- (BUSINESS WIRE) -- Spectrum Pharmaceuticals (NasdaqGM: SPPI), a commercial-stage biotechnology company with a focus in oncology, today announced ZEVALIN® (ibritumomab tiuxetan), a CD20-directed radiotherapeutic antibody, received approval from the U.S.
Comments
Log in or sign up to get involved in the conversation. It's quick and easy.